Peter Nash
Tweet
AxSpA SIG : Baraliakos - inflammation drives fatty lesions producing damage and osteoblastic activity
@RheumNow @APLAR2026 https://t.co/GDFSwt2IOm
Peter Nash
Tweet
Mease : future therapy - Be-Bold H2H Bime vs Rizi, Sonelokimab, Izokibep, Deucra, Zaso, Ico, TL1Ainhib
@RheumNow #APLAR2026 https://t.co/Rv5hwnQnDl
Dr. John Cush
Tweet
Novartis announced the European Commission has approved secukinumab (Cosentyx) for use in adults w/ polymyalgia rheumatica, not responding to GCs. SEC is 1st IL-17A inhibitor approved in Europe for PMR https://t.co/ASTwbSrGr2 https://t.co/JCTszYa57m
Dr. John Cush
Tweet
JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/xTlr5lrwUz
Peter Nash
Tweet
T cell clone in AxSpA Trvb9 & Trav 21 B27 pos pts - t cell engager developed
@RheumNow #APLAR2026 https://t.co/Jt7XBu3Kok
Article
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis
Peter Nash
Tweet
CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Associated T Cells in Axial Spondyloarthritis https://t.co/RPD7FkgEdQ anti-TRVB and anti-TRAV for your B27 AxSpA patients ( and needs looking at B27 positive PsA ) watch this space
Jiha Lee
Tweet
Deep learning DIXON MRI of SI joints (n=76, suspected axSpA): 5:24 min vs 19:49 for standard MRI (>70% faster). AUC 0.86 vs 0.87; specificity 98% vs 89%, but sensitivity 74% vs 84%. Faster, more accessible screening, with a sensitivity trade-off. #APLAR26 @RheumNow https://t.co/YUTQwcDmsz
Dr. John Cush
Tweet
Italian retrospective study of 562 plaque psoriasis Rx w/ biologics - 34% were obese. Primary Rx failure signif. more w/ obesity (17% vs 6%; HR 2.75). A 5 kg/m2 BMI incr assoc w/ 37% higher risk. Lower risk of failure w/ IL-17i (HR 0.49) & IL-23i (HR 0.47). Obesity not assoc w/ https://t.co/fUik6pBcnq
Dr. John Cush
Tweet
Novartis announced the European Commission has approved secukinumab (Cosentyx) for use in adults w/ polymyalgia rheumatica, not responding to GCs. SEC is 1st IL-17A inhibitor approved in Europe for PMR https://t.co/ASTwbSrGr2 https://t.co/KtH0AIatdq
Article
Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines. These guidelines emphasize earlier specialist input, methotrexate as an option, and bone protection for all PMR patients
Dr. John Cush
Tweet
EBR Journal Club: Secukinumab in Polymyalgia Rheumatica (REPLENISH)
The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal to an important RCT in rheumatology.
https://t.co/uejuXKsrWD https://t.co/SqtsxK6etR
Article
This edition: REPLENISH (secukinumab in polymyalgia rheumatica). The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal to an important RCT in rheumatology. Each review covers four domains: Does this apply to my patients? What is the risk of bias?
Dr. John Cush
Tweet
EADV abstract showed daxdilimab (anti-ILT7; on plasmacytoid dendritic cells) was effective in mod-severe discoid lupus. Ph II RCT 72 refract. DLE RCT; DAX vs PBO - ↓ CLASI-A vs placebo @24 wks. wk 4 ≥50% CLASI-A ~62% vs 24% https://t.co/gJ4drxErGD https://t.co/TexG55dDBL
Dr. John Cush
Tweet
Funny! Dr. Glaucomflecken explains the REPLENISH trial -secukinumab for the treatment of polymyalgia rheumatica https://t.co/7JDoMDJzeD https://t.co/ZBMcheSeCv
Article
On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients.
Article
Psoriatic arthritis is often underdiagnosed in those with psoriasis (PsO), leading to diagnostic delays an undertreatment. While certain factors in PsO portend a future PsA risk, a predictive profile and early intervention algorithm do not
Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Dr. John Cush
Tweet
Do biologic Rx lower risk of PsA? Metanalysis (15 studies, 124,138 psoriasis pts, 778K PYrs F/U), showed Biologic use assoc w/ lower risk of PsA (HR 0.54); best for IL-17i (0.65) & IL-12/23 or IL-23i (0.46) vs TNFi. IL-23i superior to IL-17i (HR 0.67) https://t.co/pjZZJ8yq9A https://t.co/yIwQs2FwLW
Dr. John Cush
Tweet
Amgen announced topline results from the Phase 3 OASIZ 301 study showing the efficacy of dazodalibep in Sjögren's dz, w/ signif ESSDAI improvements at wek 48. DAZO is a CD40L antagonist fusion protein https://t.co/5QPBdZivxC https://t.co/VfV873Lire
Dr. John Cush
Tweet
52 VEXAS pts Rx w/ IL‐1i, IL‐6i, or JAKi therapy judged as compl Resp (CR), partial (PR), Failure (TF). @ 6mos: 3/19 IL‐6i had CR, 4/19 PR, 7/19 TF. JAKi had 2/17 CR, 3/17 PR, 6/17 TF. No CR w/ IL‐1i or TNFαi, only 1/5 IL‐1i patients experienced PR. Only IL‐6i & JAKi had https://t.co/wqogmfeAru
Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Dr. John Cush
Tweet
17 Sept EMA CHMP recommended marketing authorisation for secukinumab (Cosentyx) in the treatment of polymyalgia rheumatica. BUT- not yet EMA approved in the EU. https://t.co/ZGUSbw06vX https://t.co/EqRwpT8Sxo
Dr. John Cush
Tweet
Chinese 52 wk study of XKH004, a novel, SC, humanized anti-17A/F in 323 active AS pts Rx q4 wks vs PBO. @ Wk 16, XKH004 was superior for ASAS40 (45.4% vs 19.4%; P<0.001), improved to 66% by wk 52. https://t.co/f7w41m4QZy https://t.co/LELo52zUb7
Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
